dc.contributor.author | Starace, Michela | |
dc.contributor.author | Iorizzo, Matilde | |
dc.contributor.author | Sechi, Andrea | |
dc.contributor.author | Alessandrini, Aurora Maria | |
dc.contributor.author | Carpanese, Miriam | |
dc.contributor.author | Bruni, Francesca | |
dc.contributor.author | Vara, Giulio | |
dc.contributor.author | Apalla, Zoe | |
dc.contributor.author | Asz-Sigall, Daniel | |
dc.contributor.author | Barruscotti, Stefania | |
dc.contributor.author | Camacho, Francisco | |
dc.contributor.author | Doche, Isabella | |
dc.contributor.author | Duque Estrada, Bruna | |
dc.contributor.author | Dhurat, Rachita | |
dc.contributor.author | Gavazzoni, Maria Fernanda | |
dc.contributor.author | Grimalt Santacana, Ramon | |
dc.contributor.author | Harries, Matthew | |
dc.contributor.author | Ioannidis, Dimitrios | |
dc.contributor.author | McMichael, Amy | |
dc.contributor.author | Fernandes Melo, Daniel | |
dc.contributor.author | Oliveira, Rui | |
dc.contributor.author | Ovcharenko, Yuliya | |
dc.contributor.author | Pirmez, Rodrigo | |
dc.contributor.author | Ramot, Yuval | |
dc.contributor.author | Rudnicka, Lidia | |
dc.contributor.author | Shapiro, Jerry | |
dc.contributor.author | Silyuk, Tatiana | |
dc.contributor.author | Sinclair, Rodney | |
dc.contributor.author | Tosti, Antonella | |
dc.contributor.author | Vano-Galvan, Sergio | |
dc.contributor.author | Piraccini, Bianca Maria | |
dc.date.accessioned | 2021-10-04T18:25:59Z | |
dc.date.available | 2021-10-04T18:25:59Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Starace, Michela; Iorizzo, Matilde; Sechi, Andrea [et al.]. Trichodynia and telogen effluvium in COVID-19 patients: results of an international expert opinion survey on diagnosis and management. JAAD International, 2021, 5, p. 11-18. Disponible en: <https://www.sciencedirect.com/science/article/pii/S2666328721000560?via%3Dihub>. Fecha de acceso: 4 oct. 2021. DOI: 10.1016/j.jdin.2021.07.006 | ca |
dc.identifier.issn | 2666-3287 | ca |
dc.identifier.uri | http://hdl.handle.net/20.500.12328/2837 | |
dc.description.abstract | Background: The cutaneous manifestations of COVID-19 may be useful disease markers and prognostic indicators. Recently, postinfectious telogen effluvium and trichodynia have also been reported. Objective: To evaluate the presence of trichodynia and telogen effluvium in patients with COVID-19 and describe their characteristics in relation to the other signs and symptoms of the disease. Methods: Patients with a history of COVID-19 presenting to the clinics of a group of hair experts because of telogen effluvium and/or scalp symptoms were questioned about their hair signs and symptoms in relation to the severity of COVID-19 and associated symptoms. Results: Data from 128 patients were collected. Telogen effluvium was observed in 66.3% of the patients and trichodynia in 58.4%. Trichodynia was associated with telogen effluvium in 42.4% of the cases and anosmia and ageusia in 66.1% and 44.1% of the cases, respectively. In majority (62.5%) of the patients, the hair signs and symptoms started within the first month after COVID-19 diagnosis, and in 47.8% of the patients, these started after 12 weeks or more. Limitations: The recruitment of patients in specialized hair clinics, lack of a control group, and lack of recording of patient comorbidities. Conclusion: The severity of postviral telogen effluvium observed in patients with a history of COVID-19 infection may be influenced by COVID-19 severity. We identified early-onset (<4 weeks) and late-onset (>12 weeks) telogen effluvium. | en |
dc.format.extent | 8 | ca |
dc.language.iso | eng | ca |
dc.publisher | Elsevier | ca |
dc.relation.ispartof | JAAD International | ca |
dc.relation.ispartofseries | 5; | |
dc.rights | 2021 Published by Elsevier Inc on behalf of the American Academy of Dermatology, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). https://doi.org/10.1016/j.jdin.2021.07.006 | en |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject.other | COVID-19 (Malaltia) | ca |
dc.subject.other | Caiguda de cabell | ca |
dc.subject.other | Pèrdua de cabells | ca |
dc.subject.other | Vessament de cabell | ca |
dc.subject.other | Alodinia cuir cabellut | ca |
dc.subject.other | Efluvi telogen | ca |
dc.subject.other | Tricodínia | ca |
dc.subject.other | COVID-19 | es |
dc.subject.other | Perdida de cabello | es |
dc.subject.other | Caída del cabello | es |
dc.subject.other | Alodinia del cuero cabelludo | es |
dc.subject.other | Efluvio telógeno | es |
dc.subject.other | Tricodinia | es |
dc.subject.other | COVID-19 | en |
dc.subject.other | Hair loss | en |
dc.subject.other | Hair shedding | en |
dc.subject.other | Scalp allodynia | en |
dc.subject.other | Telogen effluvium | en |
dc.subject.other | Trichodynia | en |
dc.title | Trichodynia and telogen effluvium in COVID-19 patients: results of an international expert opinion survey on diagnosis and management | en |
dc.type | info:eu-repo/semantics/article | ca |
dc.description.version | info:eu-repo/semantics/publishedVersion | ca |
dc.rights.accessLevel | info:eu-repo/semantics/openAccess | |
dc.embargo.terms | cap | ca |
dc.subject.udc | 61 | ca |
dc.subject.udc | 616.9 | ca |
dc.identifier.doi | https://dx.doi.org/10.1016/j.jdin.2021.07.006 | ca |